Participation In Congress Research Articles

Musa Jarullah Bigiyef and the Islamic Congresses (1926-1931)

Musa Carullah Bigiyef (1875-1949) Kazan’ın Rostov şehrinde doğmuş; Buhara, Mısır, Hicaz ve Hindistan’da tahsil görmüş; hayatını İslami ilimlere ve Müslümanların çeşitli dini, siyasi, sosyal ve kültürel meselelerine adamış bir ilim adamıdır. O Kur’ân ilimleri, Tefsir, Hadis, Kelam, Fıkıh, Fıkıh Usulü, Siyer ve İslam Tarihi, Arap dili ve edebiyatı gibi pek çok alanda eserler yazmış; içinde yaşadığı toplumun ve İslam dünyasının çeşitli düşünsel ve siyasal sorunları hakkında birtakım milli ve milletlerarası toplantılara katılmıştır. Elinizdeki makalede Musa Carullah’ın 1926-1931 yılları arasında toplanan İslam kongreleriyle ilişkisi ele alınacaktır. Bu kongrelerden birincisi Türkiye Büyük Millet Meclisi’nin 3 Mart 1340 (1924) tarih ve 431 sayılı kanunla hilafeti lağvetmesi üzerine, bu karara tepki olarak başta el-Ezher yöneticileri olmak üzere Mısır dinî eğitim kurumları temsilcileri tarafından önerilen ve 13-19 Mayıs 1926 tarihleri arasında Kahire’de toplanan Hilafet Kongresi’dir (el-Mu’temerü’l-İslâmiyyü’l-Âmm li’l-Hilâfeti). Musa Carullah, Mısırlı kongre tertip heyeti tarafından bu toplantıya davet edilmiş, ancak yine Mısırlı yetkililer tarafından ülkeye giriş vizesi verilmediği için söz konusu toplantıya katılamamıştır. Bazı kişiler Musa Carullah’ın Rusya’daki Bolşevik yönetime muhalif olduğunu, ona Mısır’a giriş vizesi vermenin ise Mısır’ın Rusya’yı karşısına alması demek olacağını, Mısırlı yetkililerin de bu durumdan kaçınmak için Musa Carullah’a vize vermediklerini ileri sürmüşlerdir. Biz bu makalede söz konusu iddianın gerçeği tam yansıtmadığını, Musa Carullah’a vize verilmemesinin asıl sebebini Mısır’ın Rusya’dan çekinmesinde değil; onun İngiliz gölgesindeki Mısır yönetimine, Mısır Kralı Fuâd’ın (1868-1936) “Yeni İslam Halifesi” seçilmesi ihtimaline ve el-Ezher ulemasının hilafet hakkındaki genel yaklaşımlarına karşı olmasında aramak gerektiğini ileri sürdük ve Musa Carullah’in genel olarak İslam hilafeti, özel olarak Osmanlı hilafeti hakkındaki görüşleri ile bu toplantıyı düzenleyen Ezher uleması ve Mısırlı yetkililerin hilafete yaklaşımları hakkındaki değerlendirmelerini incelemeye çalıştık. Burada ele alınan ikinci kongre 7 Haziran-5 Temmuz 1926 tarihlerinde Mekke’de toplanan Dünya Müslüman Kongresi’dir (Mu’temeru’l-âlemi’l-İslami). Dönemin ulaşım imkânları dikkate alındığında Mısır’da düzenlenen Hilafet Kongresi ile zaman bakımından çatışacak tarzda organize edilen bu kongre, kendisini Hicaz Kralı olarak ilan eden Abdülaziz İbnü’s-Suûd’un (1880-1953) İslam dünyasındaki meşruiyetini pekiştirmek amacıyla gerçekleştirdiği bir toplantıdır. Bu kongrede başta Mekke ve Medine olmak üzere Hicaz bölgesinin imarı ve hac organizasyonunun iyileştirilmesi gibi kamu düzeniyle ilgili pratik ve dâhili birtakım konular tartışılmıştır. Musa Carullah vize sorunları sebebiyle biraz geç kalmış olsa da bu kongreye katılmış ve çeşitli defalar söz alarak bazı konular hakkındaki görüşlerini dile getirmiştir. Makalede incelenecek son kongre ise 7-17 Aralık 1931 tarihlerinde Kudüs’te toplanan Genel İslam Kongresi’dir (el-Mu’temeru’l-İslâmiyyü’l-Âmm). Kudüs Müftüsü Hacı Emin el-Hüseynî (1897-1974) tarafından Müslümanlar arasında birlik ve kardeşlik duygularını geliştirmek, dış göçlerle günden güne sayıları artan Yahudilere karşı Filistin topraklarını savunmak, Kudüs’te bir İslam üniversitesi kurmak ve Hicaz demiryolunu tamir etmek gibi İslam dünyasını ilgilendiren bazı siyasi ve ekonomik konuları tartışmak amacıyla düzenlenen bu kongreye Musa Carullah Çin Türkistan’ı ve Finlandiya Müslümanları temsilcisi olarak katılmıştır. Elinizdeki makalede Musa Carullah Bigiyef’in yukarıda zikredilen kongrelere katılımı, bu kongrelerdeki müzakereleri ve onlar hakkındaki değerlendirmeleri ayrıntılı bir şekilde incelenmeye ve bu konularla ilgili bazı yanlışlar düzeltilmeye çalışılacaktır.

Boris Hessen’s Participation in the Second International Congress on the History of Science and Technology (1931)

From 29 June-3 July 1931, the Second International Congress of the History of Science and Technology took place at the Science Museum in London. It was marked by the participation of a large and representative delegation of scientists and philosophers from the Soviet Union, led by the well-known revolutionary Nicolai Bukharin. However, the contribution that stood out the most in this event was that presented by Boris Hessen, due to his instigating analysis and the set of propositions made, suggesting a reassessment of Newton’s Principia in the light of its context and its economic (industrial) motivations and social. After highlighting the list of works presented by the Soviet delegation, we will focus on Boris Hessen’s contribution, also looking at Book II of the Principia to try to relate some of the problems studied by Newton with their technological applications.

Hacia una renovada mirada de la obra y pensamiento de Marshall McLuhan en América Latina

 The central theme of our text is the presence of a shadow in the communication academy in Latin America: the shadow of Marshall McLuhan. In the first section, we refer to some anecdotes about McLuhan’s participation in the First World Congress on Communication, held in 1974, in Mexico. This allows us to narrate how the first degree in communication sciences was conceived. In the second section, we identify some events that we consider particularly significant in the recovery of McLuhan’s work and thought in Latin America. In Latin America we must recover the questions that this wonderful visionary and philosopher of communication formulated. This will allow us to recover a large part of the time we have lost.

Report on participation in the 41st ESPEN Congress

Report on participation in the 41st ESPEN Congress

В орбіті європейської філософії освіти: погляд українського учасника конгресу 2018 року

The author of article shares the impressions of participation in the 8th congress of the Polish society of philosophical pedagogics of Bronislav F. Trentovsky devoted to the 100-anniversary of the Polish philosophy of education which took place with participation of communities of Poland, Great Britain, Ukraine. Acted as organizers the Ministry of science and the Higher education of Poland, Ministry of Education and Science of Great Britain. The attention to communities of theoretical philosophical and cultural approaches of the European researchers, but different results in practical activities of scientific and practical workers is focused that can be tracked by results of sociological researches on questions of priorities of the choice of training in higher educational institutions of Europe and, in particular, Poland. They testify in favor of the choice of the Polish higher educational institutions and desire of the Ukrainian students graduates to remain after the end of training in Poland. The purpose of article is identification of methodological opportunities of the analysis of an educational perspective diversely of communicative action of Jürgen Habermas which allows to consider educational institutions together with subjects of communicative and strategic actions.
 In conclusions it is emphasized that the regulatory construct of perfect communicative community offered by Habermas focuses agents and addressees of educational and educational actions on reaching consensus in understanding of prospects of development of educational institutions. At the same time, this theory demands addition with methodological practices of N. Luhmann in which theory of self- reference social systems educational institutions and, first of all, an educational system, are considered as self-reference communication during which internal paradoxes educational and educative the practice which are wrongly interpreted in system self-descriptions as organizational and institutional and such which demand reformatory efforts from the outside though it is possible to eliminate such paradoxicality through selection of meanings of own autopoiesis come to light.

Poland’s Participation in 25th IPSA World Congress in Brisbane in 2018 (Short Facts)

Poland’s Participation in 25th IPSA World Congress in Brisbane in 2018 (Short Facts)

Дорадчі з’їзди інженерів служби рухомого складу і тяги: діяльність Л.М. Леві

An up-to-date task of modern historical science is a comprehensive study of prominent personalities having made a significant contribution to the formation and development of world science. The article is devoted to the analysis and systematized generalization of a set of scientific facts that objectively characterize various aspects of the activities of outstanding railroad engineer Liudwih Mavrykiiovych Levi in the consultative congresses of the rolling stock department engineers. In the history of science and technology, L.M Levi is known as a prominent locomotive designer, who almost all his life devoted to the development and improvement of locomotives. While preparing this paper chronological, typological, comparative methods of historical knowledge, as well as the classification and systematization of historical sources and bibliographic material which allowed to systematize and critically evaluate the used sources have been applied. Using these methods we highlighted the main point in the current state of studying the topic and the results of other researchers, characterized previous works on this problem and clearly singled out issues not having been sufficiently studied yet. The sources analysis made it possible to give an objective appraisal of the contribution made by L. Levi during his participation in the consultative congress of rolling stock and traction engineers. His role in solving the problems on implementing the “Compound system” on steam engines has been shown. Further development and improvement of which became possible only with the introduction of steam. There was an increase in traction force of locomotives and rolling stock of freight trains. It was found that thanks to the personal contribution of L. M. Levi to the unification of parts for different types of rolling stock, water supply and signaling devices, there was a reduction in the operating costs of railways. This was achieved thanks to the mass production of spare parts, as well as individual locomotives and wagons with the help of specially adapted workshops. The study of transport science through the biography of a scientist, is an integral part of a complex of diverse knowledge, involves the use of a systematic approach as a methodological means of scientific knowledge. It opens up the possibility to combine the structure and content of empirical tools from one point of view with theoretical ideas and requires the consideration of controversial views on the inheritance of national railway scientists and L.M. Levi in particular.

Belgický teolog a geolog Henry de Dorlodot (1855-1929) a evoluční vznik člověka

This study presents the life and work of the Belgian geologist and professor of dogmatic theology Henry de Dorlodot (1855–1929). The author of this study presents the life of this thinker and highlights his active participation in the World Darwinist Congress in Cambridge in 1909. Dorlodot published his work about the evolution of fauna and flora from the point of view of Catholic Orthodoxy in 1921. This was the reason for an investigation by the Pontifical Biblical Commission, followed by one from the Holy Office. Dorlodot did not publish this intended book about human evolution during his lifetime. After the discovery of the original manuscript, the book came out in 2009. This work contains a number of inspirational ideas. Dorlodot’s thoughts are based on the Tomistic concept of the relationship between the soul and the human body. Based on this theory, he argues that the fetus has been ensouled during the process of evolution at a certain moment in the body of the still inhuman mother, and thus the first human was born. His thesis wherein the first man was an ancestor for both, today’s humans and the Neanderthals, is also of interest. Dorlodot´s case probably entailed a breaking point, since at this time no one had been investigated by the Vatican authorities for having an open minded attitude to the evolution of the human body.

B3a2 Transcript Is an Independent Factor for the Achievement of a Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Imatinib in First-Line

Introduction: The achievement of a deep and sustained molecular response after treatment with tyrosine kinase inhibitors (TKI) is one of the requirements for therapy discontinuation in chronic myeloid leukemia (CML) patients.Objectives: This study aimed to evaluate the proportion of CML patients treated with imatinib in first-line that achieve MR4.5 (BCR-ABL transcripts ≤ 0.0032% in the international scale) after imatinib treatment and the predictive factors for this response. The secondary objectives were to evaluate the rate of MMR (PCR ≤0.1%), MR4.0 (PCR ≤ 0.01%), time to molecular responses, event-free survival, progression-free and overall survival.Patients and methods: This is a retrospective analysis of CP-CML patients treated in first-line with imatinib in a single center. Patients diagnosed after 2006 were managed according to the European Leukemia Net recommendations. All patients started CML imatinib within six months from diagnosis. The type of BCR-ABL1 transcript was determined by multiplex RT-PCR from cDNA synthesized from total leukocytes RNA at diagnosis. BCR-ABL transcripts by quantitative real-time polymerase chain reaction were assessed at baseline, and then every three months for the first year until reaching a stable major molecular response, then every 3-6 months. The SPSS software was used for the Cox Regression model for univariate and multivariate analysis, using backward Wald. The cumulative incidence was calculated with the R Program, with Gray test for curve comparisons. Event-free, progression-free and overall survivals were calculated with the Kaplan-Meier method, and the curves were compared with the log-rank test.Results: From January 2005 to December 2015 172 patients were treated with imatinib, median age 48 years (18-93), 55.8% male. Sokal score: 31% low-risk, 40% intermediate-risk and 29% high-risk. The median follow-up was 56 months (0-157). The Cumulative Incidence (CI) of MMR was 48% in 24 months and 84% in 5 years, while the CI of MR4.0 and MR4.5 was 63% and 51%, respectively, in 5 years. The median time to MMR, MR4.0 and MR4.5 was 16.7 (2-102), 31 (5-150) and 36 months (7-153), respectively. The univariate regression factors related to MR4.5 achievement were: age >48 years (HR 1.79; 95%CI: 1.08-2.98; P=0.023); days between diagnosis and imatinib start (HR=0.99; 95%CI: 0.98-0.99, P=0.020); e14a2 (b3a2) transcript (HR= 3.37; 95%CI: 1.67-6.81; P=0.001), which was the only factor in the multivariate analysis. Imatinib was discontinued in 96/172 (55.8%) patients due to resistance (36.5%), intolerance (20.8%), clinical trials (25%), death (15.6%) and adherence (2.1%). Eighteen out of 67 (26.8%) patients that achieved MR4.5 are currently participating in a discontinuation trial. Overall survival, PFS and EFS were 92%, 87% and 61% in 5 years.Conclusion: Approximately half of the patients that start imatinib in first-line obtain deep molecular responses within five years and could be candidates for treatment discontinuation. B3a2 transcript was an independent factor for MR4.5 achievement in the multivariate analysis, confirming the results of other studies that have reported earlier and deeper molecular responses in patients with b3a2 transcripts. DisclosuresDe Paula:Hematology and Transfusion Medicine Center, University of Campinas: Employment. Pagnano:Abbvie: Consultancy; EMS: Other: Financial support for participation in congress; Shire: Other: Lecture; Novartis: Consultancy.

Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study

Glivec was the first tyrosine kinase inhibitor (TKI) approved for chronic myeloid leukemia (CML) treatment and its efficacy has been demonstrated in a large number of trials. Generic formulations have been used recently as a more cost effective treatment, but there are few studies that have prospectively evaluated the efficacy and safety of these drugs.Aims: The present study aimed to evaluate the efficacy and safety of generic imatinib in CP-CML in first line therapy. Methods: This is a multicenter, observational, cohort-type study. The prospective cohort consisted of patients who initiated treatment with generic imatinib between January 2015 and September 2017; whereas the retrospective cohort was treated with Glivec between January 2010 and December 2011. All patients started imatinib in CP, less than six months from diagnosis. Patients were managed according to European Leukemia Net (ELN) 2009 and 2013 recommendations. The definition of the responses followed the ELN 2013 criteria. Adverse events were assessed based on the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.3, 2010. Event-free survival (EFS) was measured from starting date of treatment until loss of complete hematologic response, loss of major cytogenetic response, progression to accelerated (AP) or blast crisis (BC) or death from any cause at any time during initial therapy or discontinuation of imatinib by any cause. Patients that switched from Glivec to generic where censored. Overall survival (OS) was measured from starting date of imatinib until to the date of death from any cause while on therapy or last seen. Progression-free survival (PFS) was measured from starting date of imatinib to transformation to AP or BC or deaths while on therapy. Survival curves were calculated by the Kaplan-Meier method and compared with the log-rank test. Cox regression was used with Backward Wald Method. SPSS version 21.0 was used applying the chi-square and t-test, when adequate. All analysis considered p-value <0.05 as significant.Results:A total of 445 patients were analyzed (Glivec=285; Generic=160). The median age was 54 years (18-87) in Glivec and 50 (18-89) in the Generic group (P=0.027). Sokal score stratification in Glivec and generic groups, was respectively: low risk 14.4%/25.7%; intermediate risk 42.3%/38.2% and high risk 43.3%/36.1% (P=0.02). B3a2 frequency was 51.5% vs. 37.7% in Glivec and Generic group, respectively, and b2a2 41.4% vs. 53.8% (P=0.017). There was no significant difference in gender, Hasford, EUTOS scores and ECOG. The median follow-up was 25 months (0-71) and 11 months (0-31) for Glivec and Generic groups, respectively (P<0.0001). The median time between diagnosis and imatinib starting was 18 days (0-119) in Glivec and 27 days (0-168) in the Generic group (P= 0.015). The rate of treatment failure at 3 months according to the ELN 2013 criteria was 6.6% and 14.7% in Glivec vs. Generic (P=0.04); whereas at 6 months there were no significant differences (12.3% vs. 18.9%; P=0.09). There was no significant difference in grade 3 and 4 hematological and non-hematological toxicity during the follow-up. There were 5 and 3 cases of progression in the Glivec and Generic group, respectively. In the Cox regression multivariate analysis, the independent factors for EFS were age at diagnosis (HR=1.03; CI95% 1.00-1.07; P=0.039) and toxicity grade 3-4 (HR 3.37; CI95% 1.08-10.4; P=0.036). The initial therapy was discontinued for the following reasons, in Glivec and generic group respectively: resistance (19.7% vs. 47.5%), intolerance (15.3% vs. 23.7%), non-adherence (4.4% vs. 3.4%), death (2.0% vs. 6.8%), clinical trial (0.5% vs. 10.2%), progression (2.0% vs. 5.0%), pregnancy (0 vs. 3.4%), switch from Glivec to generic (56.1%). OS, PFS and EFS at 24 months were higher in Glivec group in comparison to Generic (99% vs. 96%, P=0.016), (98% vs. 95%, P= 0.026) and (73% vs. 58%; P<0.0001 respectively.Conclusion: The group treated with generic imatinib presented higher rate of failure at 3 months and lower OS, PFS and EFS at 24 months. Differences between the groups included a longer time to initiate treatment in the Generic group, a higher proportion of patients with b2a2 transcripts, which were related to an inferior rate of molecular responses and survival in other studies. There was no difference in the safety profile. The long-term impact in prognosis will be evaluated after a longer follow-up. DisclosuresPagnano:Shire: Other: Lecture; Abbvie: Consultancy; EMS: Other: Financial support for participation in congress; Novartis: Consultancy. Magalhaes:Novartis: Consultancy, Other: Lecture. Clementino:EMS: Other: Financial support for congress. Gaidano:AbbVie: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Morphosys: Honoraria; Amgen: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Janssen: Consultancy, Honoraria. Centrone:EMS: Other: Financial support for congress, Speakers Bureau; Bristol Meiers-Squibb: Other: Financial support for congress, Speakers Bureau; Novartis: Other: Financial support for congress, Speakers Bureau; Astra Zeneca: Speakers Bureau; Janssen: Other: Financial support for congress, Speakers Bureau. Fogliatto:Novartis: Consultancy; Roche: Consultancy, Speakers Bureau; Janssen: Honoraria, Research Funding. Giai:Pfizer: Consultancy; Novartis: Consultancy. Bortolheiro:Abbvie: Consultancy, Speakers Bureau; Sanoffi: Speakers Bureau; Novartis: Consultancy, Speakers Bureau.

Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia

Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia

Improving the Outcomes of Acute Promyelocytic Leukemia in a Limited Resources Setting: The Benefit of Early ATRA Administration in 30-Day Survival

▪ INTRODUCTIONAcute promyelocytic leukemia (APL) is the most curable acute leukemia in adults. Advancements in therapeutics such as the use of tretinoin (ATRA) and arsenic trioxide (ATO) have led to an overall survival of over 90% in 5 years. Early mortality, however, remains a major component of overall mortality in this disease and prompt recognition and initiation of adequate treatment has always been considered the most effective strategy to prevent it. Recent reports, though, have failed to show the benefit of prompt ATRA ministration in early mortality, once APL is suspected. These reports come mainly from high-income countries with swift and widespread access to health care services that are capable of recognizing, diagnosing and treating APL in a timely manner.We hypothesized, therefore, that in a lower income country, in a limited resources setting, prompt ATRA administration would improve early mortality in the setting of APL. METHODSThis is a retrospective, single-center study. We included all patients with APL diagnosis, confirmed by molecular or cytogenetics analysis treated in our institution, from January 1999 to May 2018. Until 2006, patients were treated with a modified AIDA regimen (ATRA plus mitoxantrone). After 2006, patients were treated with the International Consortium on Acute Promyelocytic Leukemia - ICAPL protocol (ATRA plus daunorubicin). This was a combined effort of the American Society of Hematology and of healthcare institutions from Latin American countries to improve outcomes in APL through improvements in therapeutics, education of healthcare professionals and expanded access to molecular diagnosis.We retrieved and reviewed patients' records for the time interval from disease presentation until the first hospital admission, and from hospital admission to the first dose of ATRA. We also looked for diagnostic variables that could be related with 30-day survival. RESULTSBetween January 1999 and May 2018, 83 APL patients were evaluated. Table 1 summarizes patients' characteristics. Medical records were available for 81/83 patients; 4 of them did not receive ATRA and died less than 7 days after their presentation. At diagnosis, median age was 37 years, 51.9% of patients were female, 26% were high-risk, 77.8% had bleeding symptoms, 72.8% had abnormal coagulation tests, and 12.3% had an elevated serum creatinine. Seventy-five percent were treated under the IC-APL protocol. Median time from disease presentation to the first hospital admission was 14.3 days (1-64 days) and median time to administration of ATRA after hospital admission was 18.2 hours (0.47-95.47 hours). Time to ATRA administration was significantly higher in patients who died in the first 30 days after diagnosis (median 27.46 vs.15.52 hours p=0.037) and who were treated with the modified AIDA (median 25.04 hours for the modified AIDA vs. 15.2 hours for the IC-APL protocol, p=0.037).Early administration of ATRA (less than 24 hours after the first hospital admission) was associated with a higher 30-day survival (89.4% vs. 63.3%, p=0.007; 75.3% for the whole cohort - Figures 1A and B). This benefit was seen mainly in patients with low or intermediate Sanz's risk score (Figures 1C and D). Serum creatinine, leukocytes count, and Sanz's risk were also predictive of 30-day survival in the whole cohort. There was no correlation between time from disease presentation to first hospital admission with 30-day survival.CONCLUSIONS: Our data support the role of early ATRA administration in the reduction of 30-day mortality in patients with recently diagnosed APL. This contrasts with previous findings from high-income countries that did not support such a benefit. We should highlight that in these cohorts the median time for ATRA administration was longer, which could explain the conflicting results. Furthermore, patients in high-income countries access health services early in their disease course, which could hamper any benefit from early ATRA administration.The correlation of early ATRA administration with the institution of IC-APL protocol underscores the importance of initiatives that promote the education of healthcare professionals and access to diagnostic tests of complex hematological diseases in low-income settings. DisclosuresPagnano:Abbvie: Consultancy; EMS: Other: Financial support for participation in congress; Novartis: Consultancy; Shire: Other: Lecture.

1-й ВСЕРОСІЙСЬКИЙ СІЛЬСЬКОГОСПОДАРСЬКИЙ З’ЇЗД У ДІЯЛЬНОСТІ ТА ТВОРЧІЙ СПАДЩИНІ Б.К. ЄНКЕНА

The article covers a separate stage in the scientific biography of Boris Karlovich Yenken – one of the founders of social agronomy, his contribution to the organization and building of agricultural researches, development of their directions and methods for the further development of agrarian science. The scientific work of B.K. Yenken during his work at the Kharkiv Breeding Station and his participation in the 1st All-Russian Agricultural Congress. The place and role of the scientist in the formation of contemporary theoretical and methodological foundations in social agronomy, breeding and seed production are shown.

Report from participation in the 14th World Congress of the International Society of Sport Psychology on 10–14 June 2017 in Seville

Report from participation in the 14th World Congress of the International Society of Sport Psychology on 10–14 June 2017 in Seville

Report from participation in the 14th World Congress of the International Society of Sport Psychology on 10–14 June 2017 in Seville

The International Society of Sport Psychology is one of the largest and oldest associations of this type in the world. The conferences organized every four years always assemble scientists and practitioners from around the world who deal with both sports psychology as well as related fi elds, such as health psychology.

Report on the Participation in 28th IVR World Congress in Lisbon, Portugal in 2017

Report on the Participation in 28th IVR World Congress in Lisbon, Portugal in 2017

The foundation of the Turkish National Student Union and the attendance of the International Student Union at the Second Warsaw Congress

In the early twentieth century many countries across the world established national student unions and sent representatives to the International Student Union. Believing this to be a fundamental need in a globalising world, the new Turkish state did not wait long before joining this union. In fact, several student associations in Turkey attended events run by the Turkish National Student Union, which was founded in the 1920s. Several student associations that had existed before the Turkish National Student Union and were founded by university students after the Second Constitutional Period, began to organise events such as debates, protests, and conferences related to the political, social, and cultural issues of the day. For instance, they organised protests against those teachers who did not support the national struggle. In 1924, these disparate unions, having previously functioned without any particular structure, were re-constituted as a national union, the Turkish National Student Union. The code of practice of this union was formed by looking at those of the unions of several European nations. Some members of this union attended the Warsaw meeting of the International Student Union in September 1924 to represent Turkey. It could be said that a culturally transformed and newly reformed Turkey was thereby presenting itself to the international world of education. The realisation of this project and Turkey’s participation in the Second Warsaw Congress is discussed in this article. Printed sources and reports of the period also allow us to take into consideration the foundation history of the Student Union established in 1919.

V. I. Charnolusky as a library scholar

To contribute to the image of Vladimir Ivanovich Charnolusky as an outstanding figure in pedagogy, librarianship and bibliography [1], the author covers his diverse library and bibliographic work in early 20 th century: his participation in the First All-Russia Congress for Librarianship (1911), Commission for Organizing Zemsky [territorial] and Urban Library Services, as well as preparation of and publishing bibliographies, including those intended for “educated readers”.

ACB2015: Biotechnology and bioeconomy for sustainable future.

ACB2015: Biotechnology and bioeconomy for sustainable future.

第14回国際放射線防護学会国際会議 (IRPA-14) への参加報告

第14回国際放射線防護学会国際会議 (IRPA-14) への参加報告